Merck Receives Patent for CRISPR Technology in China

Food and Healthcare Press Releases Tuesday April 24, 2018 08:46
DARMSTADT, Germany--24 Apr--PRNewswire/InfoQuest
  • Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells
  • Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards
  • Foundational CRISPR patents now granted in seven markets, including Canada and Europe

Merck , a leading science and technology company and leader in genome editing, today announced that the Chinese Patent Office has issued a notice granting Merck's patent application for   the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.

"Including China, we have received seven crucial patents for our foundational CRISPR technology, which defines an exciting new path for medical research and treatments for some of the toughest medical conditions, including cancer, hereditary and rare diseases," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "As a genome-editing leader, we are actively licensing our integration patents for therapeutic use, basic science research and agricultural biotechnology."

Merck, which has a 13-year history in the genome-editing field, has related patent filings for its insertion CRISPR method in the U.S., Brazil, India and Japan. The company already has had similar key patents granted in Australia, Canada, Europe, Israel, Singapore and South Korea.

This forthcoming patent in China covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence — a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.

CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging - from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.

As a company that has been highly involved in genome-editing innovation, Merck recognizes that genome-editing has resulted in major positive advancements in biological research and medicine. At the same time, the growing potential of gene-editing technologies has opened scientific, legal and societal concerns. As both a user and supplier of gene-editing technology, Merck supports research with genome editing under careful consideration of ethical and legal standards. Merck has established a   Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational   position taking into account scientific and societal issues while not blocking any promising therapeutic approaches for use in research and applications.

Merck has made significant contributions to the genome-editing field. It was the first company to offer custom biomolecules for genome editing globally (TargeTron(TM) RNA-guided group II introns and CompoZr(TM) zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

For more information on Merck's work in the genome-editing field, visit https://www.merckgroup.com/en/stories/350-anniversary-its-all-in-the-genes.html   and http://ar.merckgroup.com/2017/magazine/new-ways-of-identifying-disease .

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Almost 53,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of EUR15.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo - https://mma.prnewswire.com/media/678564/Merck_CRISPR_China.jpg

Latest Press Release

Merck Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

- New data presented at the ESMO 2018 Congress include first disclosure of results for M7824 in advanced squamous cell carcinoma of the head and neck, biliary tract cancer and esophageal cancers - Updated data also being presented include non-small cell...

Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer

Menarini Ricerche announced today the initiation of the B-PRECISE-01 clinical trial, a multicenter phase Ib study that will evaluate the safety and efficacy of MEN1611 plus trastuzumab with or without fulvestrant. The study will enroll patients with...

Don#t Miss the Signs of a Breaking Spine, Warns IOF

Osteoporosis, a disease which causes bones to become weak and fragile, is the cause of broken bones in approximately one in three women and one in five men aged over 50 worldwide. (Photo: https://mma.prnewswire.com/media/767079/IOF_Infographic.jpg...

Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt

- Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63...

Herbalife Nutrition Survey Reveals Secrets to Healthy Aging, Announces Wellness Tour to Kickstart APAC Consumers# Healthy Aging Journey

As a company whose purpose is to make the world healthier and happier, premier global nutrition company, Herbalife Nutrition, today released findings from its 2018 Asia Pacific Healthy Aging Survey. Conducted in August 2018 with 5,500 respondents aged 40...

Related Topics